This Week in Psychedelics

Did Cybin just take the top spot on the psychedelics food chain? Plus Beckley goes global and California goes back to the ballot box.

October 27, 2023

This Week...

Cybin, Inc. completed its acquisition of Small Pharma, Inc.

With the acquisition completed, Cybin now owns the industry’s largest, most advanced and well-protected deuterated DMT program.  

It also now boasts the largest IP portfolio in the psychedelic drug development sector with more than 30 patents granted and 160 patents pending, as well as two advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy. Here’s more:

Beckley Psytech announced that the first patient had been dosed in its multi-site Phase IIb study of BPL-003, a novel synthetic formulation of 5-MeO-DMT for Treatment Resistant Depression.

The study is taking place at 40 sites across Australia, Germany, Poland, Spain, the United Kingdom and the United States, and is thought to be the largest ever controlled study of 5-MeO-DMT. It follows Beckley Psytech’s receipt of the FDA’s first ever Investigational New Drug approval, which was granted in February of this year, for a Phase IIb study of a short-acting psychedelic compound. Check it out:

Activists in California announced that they’ll be submitting a new proposed ballot measure that would legalize the use, production and eventual sales of most psychedelics, including DMT, ibogaine, LSD, mescaline, psilocybin, and MDMA. It’s the third psychedelics-related initiative that organizers are trying to qualify for next year’s ballot after Governor Gavin Newsom vetoed a psychedelics legalization bill earlier this month.

The proposal, called the Psychedelic Wellness and Healing Initiative of 2024, is relatively permissive. People would no longer face criminal penalties for the use or possession of psychedelics, and they would be able to grow psychedelic plants and fungi at home for personal use. Here’s more:

Did You Know?

Did you know that psilocybin could cure cigarette smoking addiction? 

In 2013, psychiatry professor Matthew Johnson, who works at Johns Hopkins University School of Medicine, presented the preliminary results of a pilot feasibility study looking at the ability of psilocybin to treat smoking addiction. 

For the study, five cigarette-addicted participants underwent placebo-controlled psilocybin treatment with a psychiatrist. All five completely quit smoking after their first psilocybin session. At all follow up visits, which occurred up to one year later for the first four participants, it was biologically confirmed that the participants had abstained from cigarettes.

Research designed to replicate these results has continued, and with much success. You can check out some of those studies here: